Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we blitz acute diverticulitis—spot it early, stage it right, treat what matters, and prevent the encore.
We open with the why: ~200,000 US admissions/year and >$6.3B in costs. Risk stacks with age >65, obesity, NSAIDs/steroids/opioids, HTN/DM2, connective-tissue disease, and genetics. Patients roll in with LLQ pain, fever, leukocytosis, N/V.
Do-firsts in the ED/ward: IV access, analgesia (acetaminophen first; minimize opioids; avoid routine NSAIDs), antiemetics, IV fluids, and labs (CBC, BMP, UA, CRP). CT A/P with IV contrast is the diagnostic gold standard—~99–100% sensitivity/specificity—to confirm diverticulitis and flag complications.
Call the type:• Uncomplicated = localized inflammation, no abscess/perf/fistula/obstruction.• Complicated = any abscess, perforation, fistula, obstruction/stricture, peritonitis.
Who needs a bed? Admit for complicated disease, high fever (>38.5°C), marked leukocytosis, can’t tolerate PO, immunosuppression, serious comorbidity, or no home support. Outpatient is reasonable for low-risk, imaging-confirmed uncomplicated cases with reliable follow-up.
Treatment—build the supportive core:• Bowel rest → advance diet as tolerated in 2–3 days.• Antibiotics are not routine for all uncomplicated cases; reserve for high-risk (elderly, immunocompromised, persistent fever/WBC, severe comorbidity, pregnancy).• If antibiotics needed: IV ceftriaxone + metronidazole or ampicillin/sulbactam; step down to orals when improving. Typical 4–7 days (uncomplicated needing abx); 7–14 days (complicated)—tailor to response and source control.
If the core buckles—manage complicated disease:• Abscess <3 cm: IV antibiotics alone.• Abscess ≥3 cm: Percutaneous drainage + IV antibiotics (success up to ~80%).• Generalized peritonitis, failed drainage, obstruction, or clinical deterioration: Urgent surgical consult; consider resection ± primary anastomosis vs Hartmann based on stability.• Re-image at 48–72 h if no improvement.
Special populations you won’t want to miss:• Elderly: lower threshold for CT; antibiotics more often indicated; individualize operative decisions.• Immunocompromised: always treat with antibiotics, admit liberally, and involve surgery early; higher risk of rapid progression despite mild exam.
Complication radar: abscess/phlegmon, perforation/peritonitis, fistula (look for pneumaturia/fecaluria), obstruction/stricture, bleeding, sepsis/AKI. Risk rises with CRP >140 mg/L, WBC >15 ×10⁹/L, extraluminal air/fluid on CT, long inflamed segment, and major comorbidity.
Colonoscopy after the dust settles:• Complicated diverticulitis: schedule 6–8 weeks post-resolution (unless a high-quality colonoscopy was done within a year and no alarm features).• Uncomplicated: individualized—consider prior screening and symptoms; investigate early for alarm signs (weight loss, anemia, bleeding, change in caliber, persistent pain).
Secondary prevention that sticks:• High-fiber, plant-forward diet, physical activity, weight optimization, avoid tobacco, and limit chronic NSAIDs (keep aspirin for CAD when needed).• No routine mesalamine, probiotics, or rifaximin—evidence doesn’t support them.• Elective surgery isn’t about episode counting; decide based on severity, smoldering symptoms, fistula/stricture, and patient goals.
We close with the diverticulitis bundle: (1) confirm with contrast CT; (2) supportive care first (fluids, pain control, diet advance); (3) selective antibiotics—don’t overuse; (4) drain abscess ≥3 cm; (5) call surgery for peritonitis/obstruction/failed nonop care; (6) reassess at 48–72 h, re-image if stalled; (7) plan post-acute colonoscopy (complicated: 6–8 weeks); (8) lock in lifestyle prevention.
Imaging-led, selective with antibiotics, decisive with source control—treat what’s complicated, spare what isn’t, and keep patients out of the readmit loop.

In this episode of Hospital Medicine Unplugged, we dive into acute variceal bleeding—a high-stakes emergency in cirrhotic patients where seconds count and outcomes hinge on rapid, coordinated care.
We start with the crash course in recognition and stabilization: ICU-level monitoring, two large-bore IVs, and cautious transfusion—targeting a hemoglobin around 7 g/dL to avoid portal pressure spikes and rebleeding. Protect the airway early; intubate if hematemesis or encephalopathy loom.
Pharmacologic therapy doesn’t wait for endoscopy. Hit fast with octreotide (50 μg bolus → 50 μg/h infusion) or terlipressin/somatostatin if available, and start ceftriaxone 1 g IV daily to cover against bacterial translocation and sepsis. These moves—simple but evidence-based—slash early mortality and infection risk.
Then comes the endoscopic moment: perform urgent EGD within 12 hours. Band the culprit—endoscopic variceal ligation (EVL) is first-line for esophageal varices, while cyanoacrylate injection (± coils) dominates for gastric or ectopic sites. Visualization gets a boost from IV erythromycin pre-procedure. If bleeding laughs in your face—bridge with balloon tamponade or self-expanding stent while prepping for TIPS.
TIPS saves lives when all else fails or when the odds are stacked: Child-Pugh C (10–13) or B >7 with active bleeding—go early (within 24–72 hours). It decompresses the portal system, quells refractory bleeding, and buys survival time.
Once the storm calms, secondary prophylaxis takes over. Combine nonselective beta-blockers (carvedilol preferred at 12.5 mg daily) with repeat EVL every 2–4 weeks until varices vanish. No monotherapy—combo therapy halves rebleeding and boosts survival. For gastric or ectopic varices, keep repeating glue injection or move to BRTO or TIPS if anatomy and expertise allow.
Avoid the traps:• Overtransfusion—raises portal pressure.• Routine plasma/platelet correction—no proven benefit.• Early steroid use or unguarded sedation—risk spirals fast.
Complications hit early and hard—shock, infection, encephalopathy, AKI, and early rebleeding top the list. Six-week mortality can reach 40% in advanced cirrhotics, but drops sharply with prompt vasoactive therapy, antibiotics, and endoscopic control.
Predict death early: Child-Pugh C, MELD ≥19, active bleeding at endoscopy, transfusion >4 units, or renal/hepatic failure—each turns the curve downward. These patients may benefit from pre-emptive TIPS and aggressive ICU support.
Special plays:• GOV1 (lesser curvature) → treat like esophageal varices (EVL).• GOV2/IGV1 (fundal) → cyanoacrylate injection ± coil; consider BRTO if available.• Ectopic varices → tailored endoscopic or radiologic therapy.• Non-cirrhotic portal hypertension (e.g., splenic vein thrombosis) → definitive fix may be splenectomy or stenting.
We close with the system bundle that keeps patients alive:(1) Early airway + restrictive transfusion;(2) Immediate vasoactive + antibiotic therapy;(3) Urgent endoscopy (<12 h);(4) TIPS within 72 h for high-risk;(5) NSBB + EVL combo for secondary prevention;(6) Multidisciplinary follow-up with hepatology, radiology, and ICU care.
Rapid, protocolized, and team-driven—control the bleed, decompress the pressure, and protect the liver. This is how you turn variceal crisis into survival.

In this episode of Hospital Medicine Unplugged, we tackle Prinzmetal’s (variant) angina—catch the transient ST changes, prove the spasm, stop the vasoconstriction, and prevent malignant arrhythmias.
We open with the do-firsts: targeted history (rest pain, night/early-AM clustering, hyperventilation/cold/drug triggers), ECG during pain (repeat until you catch it), high-sensitivity troponin, and continuous ST-segment/telemetry because events are brief and dangerous.
Call the diagnosis when you have the triad: nitrate-responsive rest angina, transient ischemic ECG changes (ST↑ ≥0.1 mV, ST↓, or new negative U waves in ≥2 leads), and documented coronary spasm (>90% transient constriction) spontaneously or with provocation (acetylcholine/ergonovine/hyperventilation) with prompt reversal by nitro.
Rule-out matters: coronary angiography to exclude obstructive CAD (prognosis is worse if present) and to visualize reversible spasm; consider invasive coronary function testing when microvascular disease is suspected. Keep a broad differential (pericarditis, PE, aortic dissection, myocarditis).
Risk stratify for monitored care when you see: recurrent/prolonged episodes, ventricular arrhythmias, high-grade AV block, syncope, hemodynamic instability, elevated troponin/MI, or significant comorbidity.
Treatment—build the anti-spasm core:• First-line: Calcium channel blockers (CCBs)—dihydropyridines and/or non-DHP—titrate to suppress episodes.• Add: long-acting nitrates for recurrence control.• Acute relief: rapid-acting nitroglycerin at onset.• Refractory options: magnesium or alpha-blockers in select cases.• Vascular health: statins when atherosclerosis/endothelial dysfunction is present.
Hard stops (don’t do this): β-blockers (can worsen spasm), high-dose aspirin, short-acting DHP CCBs, nitrates within 24–48 h of PDE-5 inhibitor use, and routine NSAIDs for pain.
Monitoring that saves lives: continuous ST/arrhythmia surveillance to catch fleeting ischemia plus VT/VF or high-grade block; be ready for ACLS. Trend troponin if symptoms/ECG suggest injury. Use nitrates during provocation testing and keep reversal agents at hand.
Provocation testing—when spontaneous capture fails: carefully performed acetylcholine/ergonovine challenge in the cath lab with immediate access to intracoronary nitro; a positive test reproduces angina + ischemic ECG + angiographic spasm with full reversal.
Complications you can’t miss: MI from prolonged spasm, malignant ventricular arrhythmias, syncope, and sudden cardiac death. High-risk phenotypes (diffuse ST↑, aborted SCD) need aggressive suppression and electrophysiology input.
Discharge plays (prevent the next hit): smoking cessation (most potent risk factor), avoid triggers (cocaine, triptans/ergots/serotonergic agents, sympathomimetics, cold exposure), optimize lipids/BP/diabetes, and ensure adherence to CCB ± nitrate with a clear action plan for SL nitro at symptom onset.
We close with a hospital bundle: (1) capture the ECG during pain + continuous monitoring; (2) angiography to define anatomy and demonstrate reversibility; (3) CCB-anchored regimen with nitrates for backup; (4) strict β-blocker avoidance; (5) provocation testing when diagnosis is uncertain, with immediate nitrate reversal; (6) arrhythmia pathway for VT/VF/AV block; (7) trigger audit + cessation counseling; (8) targeted follow-up for recurrent events or suspected microvascular spasm.
Bottom line: identify it fast, prove the spasm, treat with CCBs + nitro, monitor relentlessly, and remove the triggers—because in Prinzmetal’s, seconds count and rhythm kills.

In this episode of Hospital Medicine Unplugged, we tackle hospital-focused TB—isolate fast, diagnose accurately, treat immediately, and coordinate with public health.
We open with the do-firsts: airborne isolation (negative pressure + N95s), notify public health, obtain CXR and 2–3 sputums for AFB smear/culture, and run first-line NAAT (Xpert MTB/RIF or Ultra) to both confirm TB and detect rifampin resistance within hours. If no sputum: induce or test extrapulmonary samples; in HIV or the critically ill, add urine LAM and site-specific molecular testing.
Isolation shortcuts that are safe: maintain airborne precautions until effective therapy + clinical improvement + serial negative smears; in low-probability cases, negative NAATs can shorten isolation per local protocol. Don’t forget source control of aerosols (patient masking for transport) and robust room engineering.
Treatment—build the bactericidal backbone:• RIPE for drug-susceptible TB: isoniazid + rifampin + pyrazinamide + ethambutol for 2 months, then isoniazid + rifampin for 4 more (6 months total). Stop ethambutol once susceptibilities confirm. Start empirically when suspicion is high or illness severe—don’t wait on cultures.• DOT (inpatient → outpatient) to secure adherence and curb resistance.• Pyridoxine with isoniazid to prevent neuropathy.
If resistance is on the table:• Triggered by prior TB, exposure to MDR-TB, high-prevalence regions, or early rifampin resistance on NAAT.• Send rapid molecular DST and culture-based DST on all isolates.• For MDR/XDR, pivot to all-oral regimens (e.g., bedaquiline-based ± linezolid/pretomanid) with expert consult—never add a single drug to a failing regimen.• Keep strict isolation until on effective therapy and improving.
Special plays:• HIV: daily TB therapy, mind rifamycin–ART interactions (use rifabutin when needed). Start ART within 2 weeks if CD4 <50 (delay for TB meningitis). Co-trimoxazole when indicated; watch for IRIS.• Renal/hepatic disease: adjust dosing, close LFT/Cr monitoring; PZA, INH, and RIF drive hepatotoxicity risk.• Pregnancy: standard therapy generally safe; monitor toxicity closely.• Extrapulmonary TB: tailor diagnostics; steroids for TB meningitis or pericarditis.
Monitoring that moves outcomes:• Monthly sputum culture until two consecutive negatives; repeat DST if still positive at 2–3 months.• Baseline → monthly LFTs, renal function; CBC if on linezolid; ECG/electrolytes if on bedaquiline.• CXR at baseline, ~2–3 months, and end of therapy to document response.• Screen and treat depression, malnutrition, substance use, and social barriers—these derail adherence.
Complications to anticipate and preempt: respiratory failure, hemoptysis, ARDS, miliary/disseminated disease, and organ-specific EPTB (CNS, bone, GU). In HIV, be ready for IRIS after ART start—recognize early, manage inflammation, continue TB therapy.
The hospital TB bundle:
Isolate immediately and notify public health.
CXR + sputum AFB/culture + NAAT (add LAM/extrapulmonary NAAT when appropriate).
Empiric RIPE now, switch per DST.
DOT handoff and discharge plan aligned with public health.
Toxicity labs monthly; culture conversion tracking.
ART timing and DDI management for HIV.
Resistance pathway (rapid DST → expert-guided, bedaquiline-based regimen).
Education + social supports to sustain adherence.
Fast, infection-controlled, and outcome-focused—isolate early, test smart, treat today, and partner with public health to break transmission and deliver cure.

In this episode of Hospital Medicine Unplugged, we cut through hospital-focused amputation decisions—prioritize life over limb, align with patient goals, and plan for function from day one.
We open with the do-firsts: stabilize sepsis and perfusion, control infection with source control, tighten inpatient glucose, and stage limb threat (WIfI, GLASS). Loop in vascular, ortho/plastics, ID, endocrine, rehab, palliative, and social/behavioral health—decisions are team sport.
Call amputation when absolute indications hit: uncontrolled sepsis, nonviable extremity, or metabolic derailment from necrosis. Relative cues: failed revascularization, intractable pain, nonfunctional limb, or nonambulatory baseline where salvage won’t restore independence.
The diagnosis-to-decision framework:• Shared decision-making: clarify best/worst/most likely outcomes; center values (comfort vs mobility, limb image vs prosthesis function).• Select the most distal level that will heal and maximize function. Minor (toe/transmetatarsal) when feasible; escalate only when biology or biomechanics demand it.• Primary amputation for survival threats; secondary after failed salvage.• Build the post-op plan before the first cut: pain pathway (regional + multimodal), dressing/edema control, early PT/OT, discharge destination, prosthetics timeline.
Level matters—function follows the joint:• Toe/forefoot: preserves gait; watch for pressure transfer and recurrence.• Midfoot (Lisfranc/Chopart) & Syme: possible but orthotics-heavy; risk of equinus/imbalance.• Below-knee (transtibial): knee preserved → highest prosthesis use and independent ambulation.• Through-knee: niche; seating advantages for some.• Above-knee (transfemoral): highest energy cost, lowest community ambulation—choose only when required.
Outcomes reality check:• Mortality is high (30-day through 5-year climbs with age/comorbidity and proximal level).• Function and quality of life track with walking ability and prosthesis use; depression/anxiety are common—screen and treat.• Rehab and prosthetics access drive return to home/work more than the incision itself.
Medical optimization pearls:• Resuscitate, revascularize if feasible, then operate—don’t chase salvage that endangers life.• Glycemic target ~<180 mg/dL, statin + antiplatelet unless contraindicated, smoking cessation, nutrition up.• Culture-guided antibiotics; debride early; involve ID for bone/joint disease.
When salvage still on the table:• Attempt only with hemodynamic stability, manageable infection, reconstructible perfusion/soft tissue, and reasonable expectation of a pain-free, functional limb.• Bail-out early if physiology worsens, tissue demarcates proximally, or function will be inferior to amputation.
Psychosocial essentials:• Name the losses, normalize grief, and offer peer support.• Embed behavioral health for depression/PTSD risk; family engagement improves clarity and follow-through.• Document goals of care and revisit as the picture evolves.
System moves that change outcomes:
Default multidisciplinary pathway (vascular-ID-rehab-behavioral).
Objective staging (WIfI/GLASS) at consult.
Life-over-limb trigger for primary amputation when unstable.
Level selection huddle with prosthetist input.
CRP-/trend-guided antibiotic and dressing protocols.
Early mobilization + rigid/semirigid dressings for edema control.
Prosthetics fast-track and scheduled socket checks.
Contralateral limb surveillance and PAD secondary prevention.
Quality dashboards (30-day complications, time to prosthesis, 1-year mobility) for continuous improvement.
We close with the takeaway: decide fast, decide together, and decide for the whole patient—survival first, then the most distal level that heals, wrapped in rehab, psychosocial support, and lifelong vascular prevention.

In this episode of Hospital Medicine Unplugged, we unpack contrast-induced nephropathy (CIN)—spot the risks, flood the kidneys (not the lungs), cut the contrast, and prevent a hospital-acquired AKI before it starts.
We open with the do-firsts: identify high-risk inpatients—those with CKD (especially eGFR <30), diabetes, heart failure, advanced age, or prior contrast within 72 hours. Draw a baseline creatinine and estimate GFR pre-procedure; no shortcuts here. Intra-arterial studies (PCI, angiography) carry more risk than IV contrast CTs.
Call CIN when you see a rise in creatinine ≥0.5 mg/dL or ≥25% from baseline within 48–72 hours post-contrast, after excluding other causes (hypotension, nephrotoxins, atheroemboli). The KDIGO AKI definition is now preferred—≥0.3 mg/dL increase within 48h or 1.5× baseline within 7 days, or urine output <0.5 mL/kg/h for ≥6h.
Pathophysiology plays:Contrast agents inflict direct tubular toxicity and indirect medullary ischemia. They cause vasoconstriction via endothelin, blunt nitric oxide, increase oxidative stress, and heighten viscosity—all of which tank renal perfusion. Tubular epithelial injury → cell swelling, necrosis, obstruction, and reduced GFR. Medullary hypoxia seals the deal.
Risk-stratify before you inject (any = high risk):• CKD (eGFR <60; highest if <30)• Diabetes (esp. with CKD)• Age >75, heart failure, volume depletion, hypotension• High contrast volume (>350 mL or >4 mL/kg), intra-arterial route, repeat studies <72h• Nephrotoxins (NSAIDs, aminoglycosides, IV amphotericin, diuretics)• Acute coronary syndromes or mechanical circulatory support during PCI
Clinical course: Creatinine rises in 24–72h, peaks day 3–5, and normalizes in 1–3 weeks if reversible. Usually non-oliguric, but oligo/anuria = severe. Dialysis need is rare (<2%), but mortality spikes if required.
Prevention—build the hydration backbone:• Isotonic saline (0.9%) at 1 mL/kg/h for 6–12h pre- and post-contrast (shorter 3+6h for urgent PCI).• Sodium bicarbonate (e.g., 250 mL 1.4% over 1h pre-, then 1 mL/kg/h for 6h post-) is an alternative, but not superior (PRESERVE, JAMA 2020).• Oral hydration ≠ enough for high-risk inpatients.• Hold nephrotoxins around the procedure.• Use the lowest feasible contrast volume and choose iso- or low-osmolar media.• Avoid repeat contrast studies within 72h.
Adjuncts (evidence weak but low-risk):• N-acetylcysteine 600–1200 mg BID, start before and continue after—may help, can’t hurt.• High-dose statins (e.g., atorvastatin 80 mg) may lower CIN risk in PCI.• No role for dopamine, fenoldopam, theophylline, or prophylactic dialysis.
If CIN develops:• Supportive only—maintain euvolemia, stop nephrotoxins, monitor urine and labs.• Dialysis only for standard triggers (refractory hyperkalemia, acidosis, overload, uremia).• No therapy reverses established CIN—time, fluids, and vigilance are your tools.• Recheck creatinine daily for 3–5 days, then space if stable.
Key lab trends:Creatinine ↑ by ≥0.5 mg/dL or ≥25% within 48–72h → peaks day 3–5 → resolves by week 2.Early shifts (≥5% in 12h) predict persistent damage. NGAL and cystatin C rise earlier but aren’t yet routine.
Hospital protocol that sticks:
Screen: all contrast orders → auto-prompt for eGFR.
Hydrate: isotonic saline 1 mL/kg/h (adjust in CHF).
Hold: nephrotoxins 24h pre/post.
Limit: contrast dose and repetition.
Check: creatinine at 48–72h post-exposure.
Document: CIN episode in EHR for future contrast precautions.
System moves:Bundle prevention into radiology workflow—automatic hydration orders, contrast dose calculators, EHR alerts for eGFR <45, and follow-up creatinine flags at 48h.
Bottom line—CIN is preventable, predictable, and high-stakes. Hydrate early, minimize contrast, skip the nephrotoxins, and track the creatinine curve. Prevention beats dialysis every time.

In this episode of Hospital Medicine Unplugged, we dive into hungry bone syndrome (HBS)—spot it early, replace hard, monitor relentlessly, and shorten the stay.
We open with the do-firsts: check calcium, phosphate, magnesium, ALP, and PTH q6–12h in the first 48–72 hours post-op; screen symptoms (paresthesias, cramps, tetany) and get an ECG for QTc if calcium is low. In dialysis patients, sync labs with the dialysis schedule.
Call the diagnosis when you see rapid, profound, and prolonged hypocalcemia (often Ca ≤7.5 mg/dL for >4 days) plus hypophosphatemia and hypomagnesemia after a sharp PTH drop (post-parathyroidectomy or thyroidectomy in thyrotoxicosis). Rising ALP over the first 1–2 weeks supports high bone turnover.
Risk-stratify who will crash (any = high risk):• SHPT on dialysis (most common, most severe)• Very high pre-op PTH and ALP, long dialysis vintage, renal osteodystrophy, younger age, heavier gland mass• PHPT with severe hypercalcemia, big adenoma, radiologic bone disease, vitamin D deficiency• Thyrotoxicosis post-thyroidectomy with low BMD and high ALP• Consider comorbidity burden and published PTH/ALP-based risk scores to guide prophylaxis
Management—build the replacement backbone:• IV calcium for symptoms, ECG changes, or severe hypocalcemia → calcium gluconate bolus then infusion, wean to high-dose oral calcium (often 3–6 g elemental/day, more if needed).• Active vitamin D early: calcitriol or alfacalcidol and add cholecalciferol to replete stores.• Magnesium matters: replace to mid-normal (hypomagnesemia blunts PTH action).• Go easy on phosphate: replete only if severe/symptomatic—overcorrection worsens hypocalcemia.• Dialysis patients: use higher-calcium dialysate, coordinate IV calcium around runs.
If the backbone buckles:• Escalate calcium infusion rate, split oral doses across the day, and consider thiazide (if euvolemic, non-CKD) to limit calciuria.• For persistent losses, reassess Mg, vitamin D dosing, and exclude hypoparathyroidism (very low PTH + hyperphosphatemia points away from HBS).
Etiology plays—treat the cause:• SHPT (CKD): ensure vitamin D analogs and optimize dialysis; manage renal osteodystrophy.• PHPT: confirm complete resection; replete vitamin D and calcium aggressively.• Thyrotoxicosis: keep magnesium topped up; anticipate transient high needs even with intact parathyroids.
HBS vs post-op hypoparathyroidism—don’t mix them up:• HBS = low Ca, low PO₄, low Mg, PTH normal/low-normal, ALP ↑.• Hypoparathyroidism = low Ca, high PO₄, low PTH, Mg usually normal. Management differs.
Monitoring & tapering that sticks:• Daily labs (sometimes q6–12h early) for Ca/PO₄/Mg/ALP; space as stable.• Trend ALP (peaks ~2 weeks) to anticipate duration.• ECG when Ca is low; watch for QTc.• Taper calcium and calcitriol slowly to avoid rebound hypercalcemia; set outpatient lab checks.
Prevention & periop moves (esp. high risk):• Replete vitamin D pre-op when feasible.• Consider bisphosphonates selectively in PHPT with very high turnover (evidence evolving).• Have a standing postop protocol for high-risk patients: preprinted orders for labs, IV→PO calcium, calcitriol start, magnesium targets, and dialysis calcium bath adjustments.
Medication pitfalls you don’t want to meet:• Under-replacing magnesium (keeps calcium low).• Over-replacing phosphate (drives calcium down).• Missing QTc prolongation.• Forgetting renal dosing and drug interactions with vitamin D analogs.
We close with the system moves: a hospital HBS bundle that (1) flags SHPT/PHPT/thyrotoxicosis cases pre-op; (2) auto-starts calcitriol + calcium with Mg targets; (3) embeds q6–12h labs early; (4) differentiates HBS vs hypoparathyroidism with a PTH/PO₄ check; (5) standardizes dialysate Ca for dialysis patients; (6) maps a taper & follow-up plan before discharge.
Bottom line—HBS is commonest after SHPT, fiercer with high turnover, and beatable with early recognition, aggressive but smart replacement, magnesium vigilance, and protocolized care.

In this episode of Hospital Medicine Unplugged, we take on pleural empyema in the hospital—recognize fast, drain early, cover smart, escalate on time—because delays and resistant bugs kill.
We set the stage: hospital-acquired empyema hits harder than community-acquired (~47% vs ~17% mortality), driven by MRSA and Pseudomonas/Gram-negatives, poly-microbial mixes, and sicker hosts. Translation: broader empiric antibiotics, earlier drainage, lower threshold for surgery.
Diagnosis you can’t miss: persistent fever, pleuritic pain, failure to improve on pneumonia therapy, and a new/large effusion. Ultrasound first (bedside, maps loculations, guides the tap), contrast CT to define split pleura/loculation or abscess, then diagnostic thoracentesis. Call it complicated when pus or pleural pH <7.20 (often with low glucose, high LDH)—that’s a drain now moment.
Empiric antibiotics—match the source:• Community-acquired: ceftriaxone (or similar) + anaerobic coverage (e.g., metronidazole) or ampicillin/sulbactam.• Hospital-acquired/post-procedural: vancomycin + anti-Pseudomonal β-lactam (piperacillin–tazobactam or cefepime). Keep anaerobe coverage.• Avoid aminoglycosides in the pleural space; no intrapleural antibiotics. De-escalate to cultures but don’t drop anaerobes unless ruled out.
Drainage—the make-or-break:• Small-bore, US-guided chest tube early for pus, low pH, large/loculated effusions.• If output stalls or loculations persist, go to intrapleural enzyme therapy (IET): tPA + DNase—combo beats monotherapy and cuts OR need.• Escalate to VATS for failure of medical therapy, thick peel, trapped lung, or advanced (organizing) stage. Early VATS shortens LOS and complications; thoracotomy for the rare, refractory cases or when VATS isn’t feasible.
Risk tools & triage: RAPID score (Renal, Age, Purulence, Infection source, Dietary/albumin) spotlights patients who need aggressive upfront therapy and early surgical consult. Layer in SOFA/qSOFA if septic.
What delays look like—and how to avoid them: atypical elders, sedation blunting exam, “treating pneumonia harder” without tapping the chest, and weekend/after-hours imaging gaps. Counterpunch with a protocol that auto-triggers US → thoracentesis → tube if pH <7.2/pus and pre-authorizes IET/VATS when drainage is inadequate.
Supportive care that moves the needle:• Nutrition (hypoalbuminemia worsens outcomes), glucose control, DVT prophylaxis, analgesia that preserves ventilation.• Daily output + imaging reassessment; tube position checks and flush protocols.• ID + Pulm + Thoracic Surgery at the table from day one.
Micro pearls: hospital bugs = MRSA, Pseudomonas, Enterobacterales, Enterococcus, anaerobes; community bugs = Streptococci (incl. anginosus group), S. aureus, anaerobes. Inoculate pleural fluid into blood culture bottles to boost yield; polymicrobial = think aspiration/anaerobes.
We close with the Empyema Bundle:(1) Flag high-risk (HAP, malignancy, postop, diabetes, renal disease, high RAPID).(2) US at bedside → diagnostic tap on any moderate/large or complex effusion.(3) Empiric antibiotics matched to source (MRSA/Pseudomonas in HAP) + keep anaerobes.(4) Early small-bore tube for pus/pH <7.2/large locules.(5) tPA + DNase if drainage stalls within 24–48 h.(6) Early VATS for non-responders or organizing stage—don’t wait for day 5–7 failure.(7) Daily goal checks (fever, WBC/CRP, output, aeration) and culture-driven de-escalation.(8) Nutrition/DVT/oral care & lung expansion to speed recovery and cut readmits.
Bottom line: source-control early, cover the right bugs, and escalate decisively. That’s how you beat hospital-acquired empyema—and keep lungs expanding, not organizing.